Goodwin Guides Parabilis Medicines on Upsized $770.5 Million Initial Public Offering and $75 Million Private Placement to Regeneron Pharmaceuticals

The Life Sciences team guided Parabilis Medicines on its upsized initial public offering of an aggregate 38,525,000 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 5,025,000 additional shares, at an initial public offering price of $20.00 per share. All of the shares of common stock were offered by Parabilis. Parabilis’ common stock began trading on the Nasdaq Global Select Market on June 10, 2026 under the ticker symbol “PBLS”. In addition to the shares sold in the initial public offering, Goodwin also advised Parabilis on of its sale of 4,166,666 shares of common stock at $18.00 per share, or 90% of the initial public offering price per share, in a concurrent private placement to Regeneron Pharmaceuticals, Inc.

The gross proceeds to Parabilis from the initial public offering, including full exercise of the underwriters’ option to purchase additional shares, before deducting underwriting discounts and commissions, and offering expenses payable by Parabilis, were $770.5 million. In addition, Parabilis received proceeds of approximately $75 million from the sale of shares of common stock in the concurrent private placement.

Parabilis Medicines is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis leverages its proprietary platform to pioneer a novel therapeutic modality, Helicons™, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines.

The Goodwin team was led by Gregg Katz, Alicia Tschirhart, and Kingsley Taft, and included Nik Shiva, Sofia Wyman, Anderson Riddick, Grace Wirth, Chris Jones, Austin Fahnestock, Eunice Chang, Elizabeth Mulkey, Tim Holahan, Austin Jones, Kristen McCarthy, Sarah Solomon, Frank Qin, Julia Shaver, Zoe Li, and Cody Foster.

For more information on the deal, please read the pricing press release, closing press release, and see coverage in Endpoints News and Fierce Biotech.